Cargando…
Update of ALDH as a Potential Biomarker and Therapeutic Target for AML
Studies employing mouse transplantation have illustrated the role of aldehyde dehydrogenase (ALDH) defining hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs). Besides being a molecular marker, ALDH mediates drug resistance in AML, which induces poor prognosis of the patients. In AML pat...
Autores principales: | Yang, Xiangchou, Yao, Rongxin, Wang, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817321/ https://www.ncbi.nlm.nih.gov/pubmed/29516013 http://dx.doi.org/10.1155/2018/9192104 |
Ejemplares similares
-
The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment
por: Zhang, Hong, et al.
Publicado: (2021) -
The rarity of ALDH
(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
por: Hoang, Van T., et al.
Publicado: (2015) -
Super enhancers: Pathogenic roles and potential therapeutic targets for acute myeloid leukemia (AML)
por: Cao, Ziyang, et al.
Publicado: (2022) -
Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023) -
ALDH1: A potential therapeutic target for cancer stem cells in solid tumors
por: Wei, Yaolu, et al.
Publicado: (2022)